Related references
Note: Only part of the references are listed.Risk of cancers during interrupted antiretroviral therapy in the SMART study
Michael J. Silverberg et al.
AIDS (2007)
Class of antiretroviral drugs and the risk of myocardial infarction
Nina Friis-Moller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Systemic lupus erythematosus
David P. D'Cruz et al.
LANCET (2007)
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3
Bryan Lau et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts:: A EuroSIDA study
Daria Podlekareva et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Liver-related deaths in persons infected with the human immunodeficiency virus -: The D:A:D study
Rainer Weber
ARCHIVES OF INTERNAL MEDICINE (2006)
The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era
A. Mocroft et al.
CLINICAL TRIALS (2006)
Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death:: a prospective cohort study
JAC Sterne et al.
LANCET (2005)
Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management
J Wajed et al.
RHEUMATOLOGY (2004)
Combination antiretroviral therapy and the risk of myocardial infarction
N Friis-Moller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies
M Egger et al.
LANCET (2002)
Share Paper
